Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peptide-pulsed cDC1 vaccine
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intrathecal
01
Overview
The peptide-pulsed cDC1 vaccine is an investigational autologous cell-based cancer immunotherapy consisting of conventional type 1 dendritic cells (cDC1s) loaded (pulsed) ex vivo with MHC class II tumor-associated peptides derived from oncogenic drivers (such as HER2 and HER3). Developed primarily by the H. Lee Moffitt Cancer Center and Research Institute, the vaccine is designed to be administered intrathecally directly into the cerebrospinal fluid to activate CD4+ Th1 adaptive immune responses against cancer cells. It is being evaluated in a Phase 1 clinical trial (NCT05809752) for the treatment of breast cancer-associated leptomeningeal disease (LMD), including HER2-positive and triple-negative breast cancer (TNBC) subtypes.
- Other names
- autologous peptide-pulsed cDC1 vaccinedendritic cell vaccineHER2/HER3 peptide-pulsed cDC1 vaccineintrathecal cDC1 vaccineintrathecal dendritic cell vaccine
02
Targets
TCR (T cell antigen receptor complex)MHC II (Major histocompatibility complex class II receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on peptide-pulsed cDC1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peptide-pulsed cDC1 vaccine.